CurrentUnitedHealthcarePolicy N/A

Lidocaine patch prior authorization

Prior authorization/notification requirements and coverage criteria for lidocaine patches (including Lidoderm and ZTLido) for treatment of neuropathic pain, affecting providers prescribing these topical patches to UnitedHealthcare members.

Policy Summary

PayerUnitedHealthcare

PolicyLidocaine patch prior authorization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2024

Next Review DateN/A

Key ActionObtain prior authorization documenting an approved diagnosis (postherpetic neuralgia or neuropathic pain) and that the patch will be applied to intact skin.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsInitial authorization duration

12 monthsReauthorization duration

brand & genericProduct scope

Brand excludedCoverage exception note

Coverage Criteria for Lidocaine Patches

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization/notification is required for lidocaine patches (including Lidoderm and ZTLido). Initial approvals are granted when both an approved diagnosis and correct application site are documented; initial authorization will be issued for 6 months.

Initial approval: must meet BOTH an approved diagnosis and application to intact skin
Approved diagnoses include post-herpetic neuralgia and neuropathic pain
Initial authorization duration: 6 months

Denial Risk

Denial Triggers

Lack of a covered diagnosis (e.g., no documentation of post‑herpetic neuralgia or neuropathic pain) or failure to document that the patch will be applied to intact skin are primary denial triggers. Requests without documentation of a positive clinical response at reauthorization may be denied.

Denied if no covered diagnosis documented (post‑herpetic neuralgia or neuropathic pain)
Denied if plan to apply patch to non‑intact skin is documented or not specified
Reauthorization denied if positive clinical response to therapy is not documented

Documentation Required

Documentation and Automated Processes

For reauthorization, documentation of a positive clinical response to therapy is required. UnitedHealthcare may also approve initial authorizations and reauthorizations based solely on prior claim/medication history, ICD‑10 diagnosis codes, and/or automated claim logic when applicable.

Reauthorization requirement: documentation of positive clinical response
UnitedHealthcare may use automated approval/re-approval based on prior claims, medication history, and diagnosis codes
Supply limits may apply

Step Therapy / Prior Authorization Sequencing

Step	Requirement
0
No specific step therapy sequencing is required. UnitedHealthcare may use automated approval or prior claim/medication history, diagnosis codes (ICD-10), and claim logic to approve initial and re-authorization; use of automated approval/re-approval processes varies by program/therapeutic class. Supply limits may be in place.

Background

Topical lidocaine patches (branded products include Lidoderm and ZTLido) are indicated for relief of pain associated with postherpetic neuralgia (PHN). Clinical guidance supports use of lidocaine patches for PHN, and evidence exists for use in other neuropathic pain conditions.

UnitedHealthcare requires prior authorization/notification for lidocaine patches; initial approvals are issued when an approved diagnosis (such as PHN or other neuropathic pain) is documented and the patch will be applied only to intact skin. Initial authorization is typically issued for 6 months, and reauthorization requires documentation of a positive clinical response.

Definitions

Postherpetic neuralgia (PHN) — definition & indication context

DefinitionPostherpetic neuralgia (PHN) — chronic neuropathic pain following herpes zoster infection; lidocaine patches (Lidoderm, ZTLido) are indicated for relief of PHN-related pain.

Covered indicationPHN is an approved diagnosis for lidocaine patch authorization when applied to intact skin.

Related indicationsEvidence supports use of lidocaine for non-PHN neuropathies (neuropathic pain).

Application requirementPatch must be applied only to intact skin for initial authorization.